MX2023002419A - Metodos para el tratamiento del embolismo por cristales de colesterol con ciclodextrinas. - Google Patents

Metodos para el tratamiento del embolismo por cristales de colesterol con ciclodextrinas.

Info

Publication number
MX2023002419A
MX2023002419A MX2023002419A MX2023002419A MX2023002419A MX 2023002419 A MX2023002419 A MX 2023002419A MX 2023002419 A MX2023002419 A MX 2023002419A MX 2023002419 A MX2023002419 A MX 2023002419A MX 2023002419 A MX2023002419 A MX 2023002419A
Authority
MX
Mexico
Prior art keywords
methods
embolization
individual
cyclodextrins
treatment
Prior art date
Application number
MX2023002419A
Other languages
English (en)
Spanish (es)
Inventor
Diana Kerwin
Jason Camm
Original Assignee
Beren Therapeutics P B C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beren Therapeutics P B C filed Critical Beren Therapeutics P B C
Publication of MX2023002419A publication Critical patent/MX2023002419A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
MX2023002419A 2020-08-27 2021-08-27 Metodos para el tratamiento del embolismo por cristales de colesterol con ciclodextrinas. MX2023002419A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063071222P 2020-08-27 2020-08-27
PCT/US2021/048072 WO2022047241A1 (en) 2020-08-27 2021-08-27 Methods for the treatment of cholesterol crystal embolization with cyclodextrins

Publications (1)

Publication Number Publication Date
MX2023002419A true MX2023002419A (es) 2023-07-11

Family

ID=80353289

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002419A MX2023002419A (es) 2020-08-27 2021-08-27 Metodos para el tratamiento del embolismo por cristales de colesterol con ciclodextrinas.

Country Status (11)

Country Link
US (1) US20230330133A1 (enExample)
EP (1) EP4203972A4 (enExample)
JP (1) JP7835735B2 (enExample)
KR (1) KR20230096975A (enExample)
CN (1) CN116322643A (enExample)
AU (1) AU2021333902A1 (enExample)
BR (1) BR112023003455A2 (enExample)
CA (1) CA3190563A1 (enExample)
IL (1) IL300806A (enExample)
MX (1) MX2023002419A (enExample)
WO (1) WO2022047241A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス， インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法
JP2024509376A (ja) * 2021-02-18 2024-03-01 ベレン セラピューティクス ピー．ビー．シー． 家族性ヘテロ接合型及びホモ接合型高コレステロール血症のシクロデキストリンによる治療方法
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
MX371073B (es) * 2012-04-13 2020-01-15 L&F Res Llc Método para utilizar ciclodextrina.

Also Published As

Publication number Publication date
AU2021333902A1 (en) 2023-03-16
CN116322643A (zh) 2023-06-23
US20230330133A1 (en) 2023-10-19
JP7835735B2 (ja) 2026-03-25
BR112023003455A2 (pt) 2023-05-02
EP4203972A1 (en) 2023-07-05
KR20230096975A (ko) 2023-06-30
IL300806A (en) 2023-04-01
CA3190563A1 (en) 2022-03-03
WO2022047241A1 (en) 2022-03-03
JP2023543133A (ja) 2023-10-13
EP4203972A4 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
Fillingham et al. Tranexamic acid in total joint arthroplasty: the endorsed clinical practice guides of the American association of hip and knee surgeons, American society of regional anesthesia and pain medicine, American academy of orthopaedic surgeons, hip society, and knee society
MX2023002419A (es) Metodos para el tratamiento del embolismo por cristales de colesterol con ciclodextrinas.
Mei et al. The efficacy of tranexamic acid for orthognathic surgery: a meta-analysis of randomized controlled trials
Xie et al. Administration of tranexamic acid reduces postoperative blood loss in calcaneal fractures: a randomized controlled trial
GB0410266D0 (en) Treatment of apoptosis
Yu et al. Can tranexamic acid reduce blood loss in cervical laminectomy with lateral mass screw fixation and bone grafting: a retrospective observational study
Sveinsson et al. Intra-arterial mechanical thrombectomy: an effective treatment for ischemic stroke caused by endocarditis
Bennett et al. Emerging indications for hyperbaric oxygen
Ferreira et al. Hexapod external fixator closed distraction in the management of stiff hypertrophic tibial nonunions
Avila et al. Lip cavernous hemangioma in a young child
Sawant et al. The impact of tranexamic acid on blood loss management in primary total knee arthroplasty: A comprehensive review
Xu et al. The combined application of pulsed electromagnetic fields and platelet-rich plasma in the treatment of early-stage knee osteoarthritis: A randomized clinical trial
Uchida et al. Preoperative steroid-related complications in Japanese pediatric patients with ulcerative colitis
Mathews et al. Surgery for hemophilia in developing countries
Harju et al. Comparison of the quality of life after minilaparotomy cholecystectomy versus laparoscopic cholecystectomy: a prospective randomized study.
MX2023002420A (es) Métodos para la prevención del embolismo por cristales de colesterol con ciclodextrinas.
Jazayeri et al. Reevaluating the role of heparin during mechanical thrombectomy for acute ischemic stroke: Increased risks without functional benefit
Walterscheid et al. Tranexamic acid in adult elective orthopaedic and complex spinal surgery: a review
Ürütük Current approach to hyperbaric oxygen therapy
Landro et al. Platelet-rich plasma for musculoskeletal disorders: No infection reported in daily practice
Jang et al. The efficacy of furosemide-based medical expulsive therapy with tamsulosin and deflazacort for symptomatic distal ureter stones
Shrader et al. Pulmonary embolism following an ankle fracture in a 9-year-old boy: a case report.
Sadeghpour et al. Effect of tranexamic acid on transfusion and blood loss in acetabular fracture surgery: a randomized clinical trial
Chandran et al. A comparative study to assess the clinical outcomes in osteoarthritis of the knee between intra-articular platelet rich plasma (PRP) injections vs intra-articular corticosteroid injections
US20070128181A1 (en) Methods of Preventing Morbidity and Mortality by Perioperative Administration of a Blood Clotting Inhibitor